Market capitalization | $50.25m |
Enterprise Value | $28.89m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 9.93 |
P/S ratio (TTM) P/S ratio | 17.27 |
P/B ratio (TTM) P/B ratio | 1.68 |
Revenue growth (TTM) Revenue growth | -91.10% |
Revenue (TTM) Revenue | $2.91m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
5 Analysts have issued a Affimed N.V. forecast:
5 Analysts have issued a Affimed N.V. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 2.91 2.91 |
91%
91%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -88 -88 |
24%
24%
|
EBIT (Operating Income) EBIT | -92 -92 |
22%
22%
|
Net Profit | -86 -86 |
27%
27%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
Head office | Netherlands |
CEO | Shawn Leland |
Employees | 78 |
Founded | 2000 |
Website | www.affimed.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.